The Effect of CYP450 Polymorphisms on Clopidogrel-Treated Patients
the MPR take:
How do CYP450 polymorphisms affect cardiovascular events among patients being treated with clopidogrel post-MI? In a new study published in the journal Circulation: Cardiovascular Genetics, a total of 2732 white and black patients were genotyped for CYP450 polymorphisms after being hospitalized for acute MI. The majority of these patients were then discharged with a prescription for clopidogrel. Among white patients who were carriers of the loss-of-function CYP2C19*2 allele, 1-year mortality was significantly increased. Among black patients who were carriers of the gain-of-function CYP2C19*17 allele, 1-year mortality was significantly increased. Researchers conclude that, depending on the patients' race, both loss-of-function and gain-of-function CYP450 polymorphisms can affect the efficacy of clopidogrel and may increase the risk of mortality.
Background- Clopidogrel is recommended after acute myocardial infarction but has variable efficacy and safety, in part related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism. Among whites, carriers of the loss-of-function CYP2C19*2 allele had significantly increased ...
READ FULL ARTICLE From Ahajournals